1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Brain Cancer Diagnostics Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Brain Cancer Diagnostics Market Analysis and Forecasts, 2023–2031
5. Key Insights
5.1. Brain Tumor Epidemiology
5.2. Current Trends in Diagnostic and Therapeutic Imaging of Brain Tumors
5.3. Technological advancements in cancer diagnostics
5.4. COVID-19 Impact Analysis
6. Global Brain Cancer Diagnostics Market Analysis and Forecasts, by Diagnostic Technique
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Diagnostic Technique, 2023–2031
6.3.1. Imaging Techniques
6.3.1.1. Magnetic Resonance Imaging (MRI)
6.3.1.2. Computed Tomography (CT) Scan
6.3.1.3. PET Scan or PET-CT Scan
6.3.1.4. (SPECT) Scan
6.3.2. Tissue Sampling/Biopsy
6.3.3. Molecular Diagnostics
6.3.4. Others
6.4. Market Attractiveness Analysis, by Diagnostic Technique
7. Global Brain Cancer Diagnostics Market Analysis and Forecasts, by Brain Cancer Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Brain Cancer Type, 2023–2031
7.3.1. Gliomas
7.3.2. Meningiomas
7.3.3. Pituitary Tumors
7.3.4. Others
7.4. Market Attractiveness Analysis, by Brain Cancer Type
8. Global Brain Cancer Diagnostics Market Analysis and Forecasts, by End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by End-user, 2023–2031
8.3.1. Hospitals
8.3.2. Diagnostic Laboratories
8.3.3. Cancer Hospitals/Centers
8.4. Market Attractiveness Analysis, by End-user
9. Global Brain Cancer Diagnostics Market Analysis and Forecasts, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Brain Cancer Diagnostics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Diagnostic Technique, 2023–2031
10.2.1. Imaging Techniques
10.2.1.1. Magnetic Resonance Imaging (MRI)
10.2.1.2. Computed Tomography (CT) Scan
10.2.1.3. PET Scan or PET-CT Scan
10.2.1.4. (SPECT) Scan
10.2.2. Tissue Sampling/Biopsy
10.2.3. Molecular Diagnostics
10.2.4. Others
10.3. Market Value Forecast, by Brain Cancer Type, 2023–2031
10.3.1. Gliomas
10.3.2. Meningiomas
10.3.3. Pituitary Tumors
10.3.4. Others
10.4. Market Value Forecast, by End-user, 2023–2031
10.4.1. Hospitals
10.4.2. Diagnostic Laboratories
10.4.3. Cancer Hospitals/Centers
10.5. Market Value Forecast, by Country, 2023–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Diagnostic Technique
10.6.2. By Brain Cancer Type
10.6.3. By End-user
10.6.4. By Country
11. Europe Brain Cancer Diagnostics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Diagnostic Technique, 2023–2031
11.2.1. Imaging Techniques
11.2.1.1. Magnetic Resonance Imaging (MRI)
11.2.1.2. Computed Tomography (CT) Scan
11.2.1.3. PET Scan or PET-CT Scan
11.2.1.4. (SPECT) Scan
11.2.2. Tissue Sampling/Biopsy
11.2.3. Molecular Diagnostics
11.2.4. Others
11.3. Market Value Forecast, by Brain Cancer Type, 2023–2031
11.3.1. Gliomas
11.3.2. Meningiomas
11.3.3. Pituitary Tumors
11.3.4. Others
11.4. Market Value Forecast, by End-user, 2023–2031
11.4.1. Hospitals
11.4.2. Diagnostic Laboratories
11.4.3. Cancer Hospitals/Centers
11.5. Market Value Forecast, by Country/Sub-region, 2023–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Diagnostic Technique
11.6.2. By Brain Cancer Type
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Brain Cancer Diagnostics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Diagnostic Technique, 2023–2031
12.2.1. Imaging Techniques
12.2.1.1. Magnetic Resonance Imaging (MRI)
12.2.1.2. Computed Tomography (CT) Scan
12.2.1.3. PET Scan or PET-CT Scan
12.2.1.4. (SPECT) Scan
12.2.2. Tissue Sampling/Biopsy
12.2.3. Molecular Diagnostics
12.2.4. Others
12.3. Market Value Forecast, by Brain Cancer Type, 2023–2031
12.3.1. Gliomas
12.3.2. Meningiomas
12.3.3. Pituitary Tumors
12.3.4. Others
12.4. Market Value Forecast, by End-user, 2023–2031
12.4.1. Hospitals
12.4.2. Diagnostic Laboratories
12.4.3. Cancer Hospitals/Centers
12.5. Market Value Forecast, by Country/Sub-region, 2023–2031
12.5.1. China
12.5.2. India
12.5.3. Japan
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Diagnostic Technique
12.6.2. By Brain Cancer Type
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Brain Cancer Diagnostics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Diagnostic Technique, 2023–2031
13.2.1. Imaging Techniques
13.2.1.1. Magnetic Resonance Imaging (MRI)
13.2.1.2. Computed Tomography (CT) Scan
13.2.1.3. PET Scan or PET-CT Scan
13.2.1.4. (SPECT) Scan
13.2.2. Tissue Sampling/Biopsy
13.2.3. Molecular Diagnostics
13.2.4. Others
13.3. Market Value Forecast, by Brain Cancer Type, 2023–2031
13.3.1. Gliomas
13.3.2. Meningiomas
13.3.3. Pituitary Tumors
13.3.4. Others
13.4. Market Value Forecast, by End-user, 2023–2031
13.4.1. Hospitals
13.4.2. Diagnostic Laboratories
13.4.3. Cancer Hospitals/Centers
13.5. Market Value Forecast, by Country/Sub-region, 2023–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Diagnostic Technique
13.6.2. By Brain Cancer Type
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Brain Cancer Diagnostics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Diagnostic Technique, 2023–2031
14.2.1. Imaging Techniques
14.2.1.1. Magnetic Resonance Imaging (MRI)
14.2.1.2. Computed Tomography (CT) Scan
14.2.1.3. PET Scan or PET-CT Scan
14.2.1.4. (SPECT) Scan
14.2.2. Tissue Sampling/Biopsy
14.2.3. Molecular Diagnostics
14.2.4. Others
14.3. Market Value Forecast, by Brain Cancer Type, 2023–2031
14.3.1. Gliomas
14.3.2. Meningiomas
14.3.3. Pituitary Tumors
14.3.4. Others
14.4. Market Value Forecast, by End-user, 2023–2031
14.4.1. Hospitals
14.4.2. Diagnostic Laboratories
14.4.3. Cancer Hospitals/Centers
14.5. Market Value Forecast, by Country/Sub-region, 2023–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Diagnostic Technique
14.6.2. By Brain Cancer Type
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis By Company (2021)
15.3. Company Profiles
15.3.1. GE Healthcare
15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. Strategic Overview
15.3.1.5. SWOT Analysis
15.3.2. Siemens Healthineers
15.3.2.1. Company Overview
15.3.2.2. Financial Overview
15.3.2.3. Product Portfolio
15.3.2.4. Strategic Overview
15.3.2.5. SWOT Analysis
15.3.3. Philips Healthcare
15.3.3.1. Company Overview
15.3.3.2. Financial Overview
15.3.3.3. Product Portfolio
15.3.3.4. Strategic Overview
15.3.3.5. SWOT Analysis
15.3.4. Thermo Fisher Scientific
15.3.4.1. Company Overview
15.3.4.2. Financial Overview
15.3.4.3. Product Portfolio
15.3.4.4. Strategic Overview
15.3.4.5. SWOT Analysis
15.3.5. Roche Diagnostics
15.3.5.1. Company Overview
15.3.5.2. Financial Overview
15.3.5.3. Product Portfolio
15.3.5.4. Strategic Overview
15.3.5.5. SWOT Analysis
15.3.6. Abbott Laboratories
15.3.6.1. Company Overview
15.3.6.2. Financial Overview
15.3.6.3. Product Portfolio
15.3.6.4. Strategic Overview
15.3.6.5. SWOT Analysis
15.3.7. Illumina, Inc.
15.3.7.1. Company Overview
15.3.7.2. Financial Overview
15.3.7.3. Product Portfolio
15.3.7.4. Strategic Overview
15.3.7.5. SWOT Analysis
15.3.8. Hologic, Inc.
15.3.8.1. Company Overview
15.3.8.2. Financial Overview
15.3.8.3. Product Portfolio
15.3.8.4. Strategic Overview
15.3.8.5. SWOT Analysis
15.3.9. Agilent Technologies
15.3.9.1. Company Overview
15.3.9.2. Financial Overview
15.3.9.3. Product Portfolio
15.3.9.4. Strategic Overview
15.3.9.5. SWOT Analysis
15.3.10. Bio-Rad Laboratories
15.3.10.1. Company Overview
15.3.10.2. Financial Overview
15.3.10.3. Product Portfolio
15.3.10.4. Strategic Overview
15.3.10.5. SWOT Analysis
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer